The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


Sustained improvement in skin symptoms up to 2 years1,a

aPALACE 3 study. Data as observed; includes all patients with baseline psoriasis BSA >3 who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24. Patients with BSA ≥3 at baseline: OTEZLA 30 mg BID, n = 92/167 (55.1%); placebo, n = 94/169 (55.6%).

  • OTEZLA provided sustained improvement in skin symptoms for up to 4 years2

OTEZLA is also indicated for moderate to severe plaque psoriasis3

See the OTEZLA difference

Real psoriasis patients, real pictures.*


Week 16 PASI-75 result

Individual results may vary.

*Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.

BID, twice daily; BSA, body surface area; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; PASI, Psoriasis Area and Severity Index.


  1. Edwards CJ, Blanco FJ, Crowley J, et al. Efficacy of Long-term (104-Week) Treatment With Apremilast in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension. Presented at: the 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC.
  2. Edwards CJ, et al. Apremilast is associated with long-term (4-year) DAS-28 (CRP) remission and improvements in skin disease: results from a phase III study in DMARD/biologic-experienced patients with active psoriatic arthritis. Ann Rheum Dis. 2017;76 (suppl 2): Abstract FRI0487.
  3. OTEZLA Summary of Product Characteristics. Stockley Park, Uxbridge, UK: Celgene Europe, Ltd; 2017.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil